Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth
ACS Infectious Diseases · 2025
DOI: 10.1021/acsinfecdis.4c00796 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Ke-Chuan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hypermag, Department of Health Technology, Technical University of Denmark, Ørsteds Plads 349, Lyngby 2800, Denmark. Hauptthemen laut MEDLINE: Probiotics, Shigella flexneri, Lacticaseibacillus rhamnosus, Formates. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Danmarks Grundforskningsfond, Novo Nordisk Fonden.
Abstract (Originalsprache)
The interplay between probiotic metabolites, host health, and inhibition of pathogens has increasingly attracted interest but remains unresolved due to the complex molecular interactions among these factors. We investigated the action of cell-free supernatants (CFSs) from two probiotic bacteria, Bifidobacterium animalis spp. lactis (B. lactis) HN019 and Lacticaseibacillus rhamnosus (L. rhamnosus) HN001 and their effect against the bacterial pathogen Shigella flexneri 2457T (S. flexneri). The CFSs from B. lactis HN019 exhibited a higher antibacterial effect against S. flexneri growth than the CFSs from L. rhamnosus HN001, independent of the carbon source utilized. This effect correlated with higher formate within the CFSs from B. lactis HN019. As expected, the antimicrobial effects of CFSs were stronger against free S. flexneri cells than for S. flexneri infecting host cells. A synergistic effect of the CFSs with additional small organic molecules such as indole-3-lactate and formate was found. Such interplay between CFSs, indole-3-lactate, and formate was reflected by altered metabolic rates by S. flexneri in the presence of B. lactis HN019 CFSs both in the solution and under biofilm-forming conditions. The synergistic effect between different components acting on S. flexneri gives reasons to believe that suitably designed mixtures of probiotic metabolic products and small-molecule effectors bear promise for successfully combating pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hypermag, Department of Health Technology, Technical University of Denmark, Ørsteds Plads 349, Lyngby 2800, Denmark.
- IFF Enabling Technologies, Edwin Rahrsvej 38, Brabrand 8220, Denmark.
- IFF Health, Global Health & Nutrition Science, Sokeritehtaantie 20, Kantvik 02460, Finland.
- Health & Biosciences, International Flavors & Fragrances, Madison, Wisconsin 53716, United States.
- Department of Chemistry, Technical University of Denmark, Kemitorvet 206, Lyngby 2800, Denmark.
ORCID-Profile: Sebastian Meier, Pernille Rose Jensen
Förderung
- Danmarks Grundforskningsfond
- Novo Nordisk Fonden
Zitieren
APA
Wang, K. C., Yde, C. C., Anglenius, H., Salli, K., Morovic, W., Poore, M., Gerdes, S., Meier, S., Jensen, H. M., & Jensen, P. R. (2025). Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00796
Vancouver
Wang KC, Yde CC, Anglenius H, Salli K, Morovic W, Poore M, et al. Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.4c00796
BibTeX
@article{Wang2025,
author = {Wang, Ke-Chuan and Yde, Christian Clement and Anglenius, Heli and Salli, Krista and Morovic, Wesley and Poore, Matthew and Gerdes, Svetlana and Meier, Sebastian and Jensen, Henrik Max and Jensen, Pernille Rose},
title = {Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth},
journal = {ACS Infectious Diseases},
year = {2025},
doi = {10.1021/acsinfecdis.4c00796}
}
EUVIMED